Idorsia Pharmaceuticals Overview
- Year Founded
-
2017
- Status
-
Public
- Employees
-
232
- Stock Symbol
-
IDIA
- Investments
-
1
- Share Price
-
$4.75
- (As of Thursday Closing)
Idorsia Pharmaceuticals General Information
Description
Idorsia Ltd is a biopharmaceutical company engaged in discovering, developing, and commercializing of medicines for unmet medical needs. The company is a biotech hub of Europe specialized in the discovery and development of small molecules, to provide new therapeutic options. The company focuses on multiple therapeutic areas which include the central nervous system, cardiovascular disorders, immunological disorders, and orphan diseases. The company's development compounds target a number of different diseases such as Resistant Hypertension, lupus, insomnia, Cerebral vasospasm, and Fabry disease. Geographically, it derives revenue from Switzerland.
Contact Information
Website
www.idorsia.comCorporate Office
- Hegenheimermattweg 91
- 4123 Allschwil
- Switzerland
Corporate Office
- Hegenheimermattweg 91
- 4123 Allschwil
- Switzerland
Idorsia Pharmaceuticals Timeline
Idorsia Pharmaceuticals Stock Performance
As of 12-Nov-2026, Idorsia Pharmaceuticals’s stock price is $4.75. Its current market cap is $1.28B with 270M shares.
(As of Thursday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $4.75 | $4.86 | $3.53 - $9.36 | $1.28B | 270M | 988K | -$1.44 |
Idorsia Pharmaceuticals Financials Summary
As of 30-Sep-2026, Idorsia Pharmaceuticals has a trailing 12-month revenue of $276M.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 2,975,175 | 2,837,872 | 1,453,137 | 1,560,915 |
| Revenue | 276,324 | 265,408 | 127,776 | 169,521 |
| EBITDA | (237,360) | (54,732) | (257,160) | (283,101) |
| Net Income | (355,875) | (134,394) | (299,550) | (331,421) |
| Total Assets | 553,275 | 588,289 | 559,909 | 595,276 |
| Total Debt | 1,593,250 | 1,600,092 | 1,390,824 | 1,432,990 |
Idorsia Pharmaceuticals Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Idorsia Pharmaceuticals Comparisons
Industry
Financing
Details
Idorsia Pharmaceuticals Competitors (63)
One of Idorsia Pharmaceuticals’s 63 competitors is Lakefront Biotherapeutics, a Formerly VC-backed company based in Mechelen, Belgium.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Lakefront Biotherapeutics | Formerly VC-backed | Mechelen, Belgium | ||||
| Protagonist Therapeutics | Formerly VC-backed | Newark, CA | ||||
| Cognition Therapeutics | Formerly VC-backed | New York, NY | ||||
| Antag Therapeutics | Venture Capital-Backed | Copenhagen, Denmark | ||||
| Bristol-Myers Squibb | Corporation | Princeton, NJ |
Idorsia Pharmaceuticals Patents
Idorsia Pharmaceuticals Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026087792-A1 | Vaccine against klebsiella pneumoniae | Pending | 27-Oct-2024 | ||
| WO-2026013167-A1 | Pharmaceutical composition comprising clostridioides difficile vaccine | Pending | 11-Jul-2024 | ||
| WO-2025261989-A1 | 1,2,3-triazole derivatives as il4i1 inhibitors | Pending | 18-Jun-2024 | ||
| WO-2025229177-A1 | Crystalline forms of an n-substituted indole derivative | Pending | 02-May-2024 | ||
| WO-2025224168-A1 | Aryl sulfone and sulfanone derivatives as orexin receptor modulators | Pending | 24-Apr-2024 | C07D401/12 |
Idorsia Pharmaceuticals Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Idorsia Pharmaceuticals Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Idorsia Pharmaceuticals Acquisitions (1)
Idorsia Pharmaceuticals’s most recent deal was a Merger/Acquisition with Vaxxilon for . The deal was made on 20-May-2020.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Vaxxilon | 20-May-2020 | Merger/Acquisition | Drug Discovery |
Idorsia Pharmaceuticals ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
22.86 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,585
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Biotechnology
Subindustry
of 431
Rank
Percentile
Idorsia Pharmaceuticals FAQs
-
When was Idorsia Pharmaceuticals founded?
Idorsia Pharmaceuticals was founded in 2017.
-
Where is Idorsia Pharmaceuticals headquartered?
Idorsia Pharmaceuticals is headquartered in Allschwil, Switzerland.
-
What is the size of Idorsia Pharmaceuticals?
Idorsia Pharmaceuticals has 232 total employees.
-
What industry is Idorsia Pharmaceuticals in?
Idorsia Pharmaceuticals’s primary industry is Biotechnology.
-
Is Idorsia Pharmaceuticals a private or public company?
Idorsia Pharmaceuticals is a Public company.
-
What is Idorsia Pharmaceuticals’s stock symbol?
The ticker symbol for Idorsia Pharmaceuticals is IDIA.
-
What is the current stock price of Idorsia Pharmaceuticals?
As of 12-Nov-2026 the stock price of Idorsia Pharmaceuticals is $4.75.
-
What is the current market cap of Idorsia Pharmaceuticals?
The current market capitalization of Idorsia Pharmaceuticals is $1.28B.
-
What is Idorsia Pharmaceuticals’s current revenue?
The trailing twelve month revenue for Idorsia Pharmaceuticals is $276M.
-
Who are Idorsia Pharmaceuticals’s competitors?
Lakefront Biotherapeutics, Protagonist Therapeutics, Cognition Therapeutics, Antag Therapeutics, and Bristol-Myers Squibb are some of the 63 competitors of Idorsia Pharmaceuticals.
-
What is Idorsia Pharmaceuticals’s annual earnings per share (EPS)?
Idorsia Pharmaceuticals’s EPS for 12 months was -$1.44.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
